CapsoVision Business Summary

CapsoVision, Inc. (NASDAQ: CV) is a commercial-stage medical technology company specializing in advanced gastrointestinal (GI) diagnostic imaging. The company generates revenue primarily through a transaction-based model centered on the sale of its flagship CapsoCam Plus, a single-use, orally ingestible capsule endoscope, alongside its proprietary CapsoCloud and CapsoView software platforms. Its primary business segments are divided between small bowel diagnostic hardware and cloud-based AI-assisted reading modules, the latter of which recently underwent FDA 510(k) submission to enhance clinical workflow efficiency. CapsoVision differentiates itself in the market as the only provider of 360-degree panoramic lateral imaging, positioning it as a high-accuracy alternative to traditional forward-facing capsules. Its direct competitors include Medtronic (PillCam), Olympus Corporation, and Check-Cap; relative to these industry giants, CapsoVision occupies a specialized niche focused on wire-free, cloud-hosted diagnostics that eliminate the need for external receiver equipment. The leadership team is anchored by Co-Founder and CEO Kang-Huai (Johnny) Wang, a semiconductor industry veteran who previously served as the company’s CTO and held executive roles at ESS Technology and Divio, Inc. In late 2025, the company strengthened its financial oversight by appointing David Garcia as Senior Vice President of Finance, bringing over 20 years of experience from Matterport and Align Technology. Global sales operations are led by SVP Douglas Atkinson, who previously held senior leadership positions at Medtronic and Stryker. The company is governed by a board chaired by Chen Lung Tsai and includes notable directors such as Julia Gouw and Michele Harari. Since its July 2025 initial public offering, CapsoVision has attracted significant institutional interest, building on a $118 million venture-backed foundation from investors including China Venture Capital Co. Ltd. and tech luminaries like Weili Dai and Eli Harari.